Frenova Renal Research, a research and development division owned by Fresenius Medical Care North America, will be collaborating with drug development company Covance Inc. to find more effective treatments for chronic kidney disease and end-stage renal disease patients.

Covance will use its analytics capabilities to conduct research on behalf of its biopharmaceutical clients using Frenova’s database that comprises more than 393,000 CKD patients and 980,000 ESRD patients, according to the companies.The data will be used to better understand the burden of illness, treatment patterns, medication adherence, and comparative safety and efficacy of medical treatments in the real world. The collaboration will also help new drug sponsors assess protocol feasibility, select study sites, conduct targeted patient recruitment and determine optimal sample size.

“With this unique combination of data and analytics, we can look at how patients actually use medicines day-to-day, which includes the reality of less-than-perfect adherence,” said Marc Ginsky, vice president and general manager for Covance Market Access Services. “We can then explore real-world safety and effectiveness, comparing therapies head-to-head and in the full range of patients, not just those who meet narrow inclusion and exclusion criteria.”

Frenova Renal Research maintains an extensive database of “de-identified” renal patient data, meaning that any identifying information has been removed in order to protect the privacy of patients.